ANZCTR search results

Chronic kidney disease (CKD), defined as an eGFR <60 ml/min/1.73 m2 and/or the presence of kidney damage (albuminuria or proteinuria) for at least 3 months, is a major public health problem affecting approximately 1.6 million Australian adults. Of these affected individuals, approximately 930,000 have stages 3-4 CKD (eGFR 15-60 mL/min/1.73 m2). CKD patients have a greatly increased risk of adverse renal and cardiovascular (CV) outcomes, even in its early stages. CKD patients are at increased risk of progression to end-stage kidney disease (ESKD). The incidence of ESKD is increasing in Australia by 6% per annum. Apart from an increased risk of ESKD, the presence of CKD is one of the most potent known risk factors for cardiovascular disease (CVD), such that individuals with CKD are more likely to die, mostly from CVD, than survive to the point of needing dialysis or kidney transplantation. A reduction in eGFR <60 ml/min/1.73 m2 is associated with increased risks of all-cause and CV mortality. The CKD-FIX trial aims to critically examine the efficacy and safety of allopurinol as an agent to slow the progression of chronic kidney disease (CKD).

To compare patient outcome, the primary endpoint being the incidence of post-operative nausea and vomiting (PONV), associated with the use of either neostigmine and glycopyrrolate or sugammadex for the routine reversal of neuromuscular block following laparoscopic gynaecological surgery. Secondary outcomes to be assessed include readiness to discharge, return of normal bowel function, patient recovery and well-being.

To compare the effectiveness of different physical activity strategies in increasing home care clients’ levels of physical activity in the short and long term; and explore their contribution to the achievement of functional independence.

This project will primarily examine whether a group psychological treatment for clinical perfectionism is better than being on an eight-week waitlist in a) reducing individuals' levels of clinical perfectionism, b) reducing their symptoms of anxiety, depression, and/or eating concerns and c) improving their quality of life. It is predicted that the group treatment will lead to greater reductions in clinical perfectionism, greater reductions in psychological symptoms, and greater increases in quality of life compared to the waitlist control condition. Additionally this project will examine whether group psychological treatment for clinical perfectionism produces treatment-related change in each individual and whether this is clinically significant.

This project is designed to assess myocardial ischemia in various populations of patients with renal disease. These cohorts of patients have significant cardiovascular morbidity and mortality. It is believed that apart from epicardial coronary disease, they also have microvascular or small vessel ischemia. Dialysis is thought to be a major contributor in acceleration of their cardiovascular disease, however even after renal transplantation, there cardiovascular morbidity and mortality does not mirror the general population. We are going to assess myocardial ischemia using cardiac MRI and blood oxygen level dependent imaging. This uses intrinsic contrast of deoxy-hemoglobin to assess ischemia. We are going to assess it in patients on dialysis regardless of their cardiovascular symptoms as this group of patients have significant disease despite lack of traditional cardiac symptoms. We are also going to look at patients being evaluated for renal transplant. In this population, we can directly compare this relatively new technique with traditional method of ischemia assessment. We believe this technique will provided added information to already existing imaging modalities as it looks at oxygenation of the myocardium, which precedes development of ischemia. Our third study, evaluates patients after their renal transplant, examining markers that may predict cardiovascular morbidity and mortality in this group. This study is the evaluation for renal transplant cohort and is associated with ACTRN12611000783921 and ACTRN12611000785909

This project is designed to assess myocardial ischemia in various populations of patients with renal disease. These cohorts of patients have significant cardiovascular morbidity and mortality. It is believed that apart from epicardial coronary disease, they also have microvascular or small vessel ischemia. Dialysis is thought to be a major contributor in acceleration of their cardiovascular disease, however even after renal transplantation, there cardiovascular morbidity and mortality does not mirror the general population. We are going to assess myocardial ischemia using cardiac MRI and blood oxygen level dependent imaging. This uses intrinsic contrast of deoxy-hemoglobin to assess ischemia. We are going to assess it in patients on dialysis regardless of their cardiovascular symptoms as this group of patients have significant disease despite lack of traditional cardiac symptoms. We are also going to look at patients being evaluated for renal transplant. In this population, we can directly compare this relatively new technique with traditional method of ischemia assessment. We believe this technique will provided added information to already existing imaging modalities as it looks at oxygenation of the myocardium, which precedes development of ischemia. Our third cohort, evaluates patients after their renal transplant, examining markers that may predict cardiovascular morbidity and mortality in this group. This trial is the end stage renal disease cohort and is linked to ACTRN12611000783921 and ACTRN12611000786998

The purpose of this study is to measure drug blood levels in health male volunteers over a 14 day period. in addition, it is intended to assess the safety and effect of the drug in study subjects over a 90 day period.

This project is designed to assess myocardial ischemia in various populations of patients with renal disease. These cohorts of patients have significant cardiovascular morbidity and mortality. It is believed that apart from epicardial coronary disease, they also have microvascular or small vessel ischemia. Dialysis is thought to be a major contributor in acceleration of their cardiovascular disease, however even after renal transplantation, there cardiovascular morbidity and mortality does not mirror the general population. We are going to assess myocardial ischemia using cardiac MRI and blood oxygen level dependent imaging. This uses intrinsic contrast of deoxy-hemoglobin to assess ischemia. We are going to assess it in patients on dialysis regardless of their cardiovascular symptoms as this group of patients have significant disease despite lack of traditional cardiac symptoms. We are also going to look at patients being evaluated for renal transplant. In this population, we can directly compare this relatively new technique with traditional method of ischemia assessment. We believe this technique will provided added information to already existing imaging modalities as it looks at oxygenation of the myocardium, which precedes development of ischemia. Our third cohort, evaluates patients after their renal transplant, examining markers that may predict cardiovascular morbidity and mortality in this group. This trial is the post transplant cohort and is linked to trial ACTRN12611000786998 and ACTRN12611000785909

The aim of this project is to study a new way of cleaning the bowel prior to colonoscopy. Current methods of cleaning the bowel are very effective but have some limitations. Bowel preparation currently involves drinking a large volume of salty tasting fluid which many patients do not like. An alternative method involves drinking a smaller volume of solution that can cause complications associated with dehydration and decreased salt levels within the body. In this study we will evaluate a new way of cleaning the bowel involving the use of a more gentle tablet laxative and diet restrictions in the three days before your colonoscopy. We are also interested in how you as the patient feel about this method of cleaning the bowel and we will ask you to fill in a questionnaire prior to your colonoscopy. The laxative we are using in this trial (Dulcolax) is freely available and works by stimulating the colon to pass bowel motions. It is a safe drug that is proven to be effective in helping empty the bowel. Dulcolax (bisacodyl) is approved by the Therapeutic Goods Administration of Australia to treat constipation and evacuation of the bowel. This study will be conducted at The Western Hospital Footscray. 200 people will be asked to participate in this trial.

This study aims to compare two different radiotherapy regimes following radical prostatectomy in men with prostate cancer. Who is it for? You may be eligible to join this study if you a male aged 18 years or above who has undergone a radical prostatectomy (RP) for prostate cancer, and are able to start radiotherapy within 4 months of RP. Study details Participants in this study will be randomly (by chance) allocated to one of two groups. Participants in one group will receive the current standard of care treatment, which consists of adjuvant radiation therapy (ART) commenced within 4 months of radical prostatectomy. Participants in the other group will instead undergo active surveillance, where salvage radiotherapy (SRT) will not commence until Prostate Specific Antigen (PSA) reaches a level greater than 0.2ng/ml. Both radiotherapy regimes will be delivered once per day over approximately 6.5 weeks. Quality of life self-assessment questionnaires, Hospital Anxiety and Depression Score and toxicity will be assessed at baseline, the end of radiotherapy and annually for 5 years. Patients will be seen by their doctor 6 monthly for the first 5 years, then annually for the next 5 years. A blood test measuring PSA is done 3 monthly for the first 5 years for patients randomised to early SRT, than 6 monthly from years 5-10.